IDXX vs MYGN
Idexx Laboratories Inc. and Myriad Genetics Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | IDXX | MYGN |
|---|---|---|
| Revenue | $4.3B | $824.5M |
| Net income | $1.1B | $-365.9M |
| Gross margin | 61.8% | 69.9% |
| Net margin | 24.6% | −44.4% |
| Return on equity | 66.2% | −68.5% |
| Diluted EPS | $13.08 | −$3.95 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | $1.1B | · |
| Equity | $1.6B | $368.0M |
| Net debt / equity | 0.17× | −0.08× |
| Current ratio | 1.23× | 2.49× |
| Revenue CAGR 5y | 9.7% | 8.2% |
| Profit CAGR 5y | 12.7% | · |
IDXX bills 5.2× the revenue of MYGN, and MYGN closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | IDXX | MYGN |
|---|---|---|
| FY2025 | $4.3B | $824.5M |
| FY2024 | $3.9B | $837.6M |
| FY2023 | $3.7B | $753.2M |
| FY2022 | $3.4B | $678.4M |
| FY2021 | $3.2B | $690.6M |
| FY2020 | $2.7B | $557.1M |
| FY2019 | $2.4B | $638.6M |
| FY2018 | $2.2B | $851.1M |
| FY2017 | $2.0B | $743.7M |
| FY2016 | $1.8B | $728.7M |
Bottom line
| Fiscal year | IDXX | MYGN |
|---|---|---|
| FY2025 | $1.1B | $-365.9M |
| FY2024 | $887.9M | $-127.3M |
| FY2023 | $845.0M | $-263.3M |
| FY2022 | $679.1M | $-112.0M |
| FY2021 | $744.8M | $-27.2M |
| FY2020 | $581.8M | $-223.6M |
| FY2019 | $427.7M | $-199.5M |
| FY2018 | $377.0M | $4.6M |
| FY2017 | $263.1M | $133.3M |
| FY2016 | $222.0M | $17.4M |
18 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$3,479,202,000 | IDXX |
| FY2024 | +$3,059,904,000 | IDXX |
| FY2023 | +$2,907,753,000 | IDXX |
| FY2022 | +$2,688,924,000 | IDXX |
| FY2021 | +$2,524,760,000 | IDXX |
| FY2020 | +$2,149,555,000 | IDXX |
| FY2019 | +$1,768,308,000 | IDXX |
| FY2018 | +$1,362,142,000 | IDXX |
| FY2017 | +$1,225,358,000 | IDXX |
| FY2016 | +$1,046,723,000 | IDXX |
| FY2015 | +$861,392,000 | IDXX |
| FY2014 | +$763,307,000 | IDXX |
| FY2013 | +$598,858,000 | IDXX |
| FY2012 | +$680,138,000 | IDXX |
| FY2011 | +$722,684,000 | IDXX |
| FY2010 | +$701,308,000 | IDXX |
| FY2009 | +$668,985,000 | IDXX |
| FY2008 | +$697,503,000 | IDXX |
IDXX has reported the higher revenue in every one of these 18 fiscal years. The gap has widened since the earliest year compared.
18 of 18 comparable fiscal years — a year missing data on either side is not counted.
18 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +69.0 pp | IDXX |
| FY2024 | +38.0 pp | IDXX |
| FY2023 | +58.0 pp | IDXX |
| FY2022 | +36.7 pp | IDXX |
| FY2021 | +27.1 pp | IDXX |
| FY2020 | +61.7 pp | IDXX |
| FY2019 | +49.0 pp | IDXX |
| FY2018 | +16.5 pp | IDXX |
| FY2017 | −4.5 pp | MYGN |
| FY2016 | +10.1 pp | IDXX |
| FY2015 | −3.8 pp | MYGN |
| FY2014 | +1.2 pp | IDXX |
| FY2013 | −9.0 pp | MYGN |
| FY2012 | −10.2 pp | MYGN |
| FY2011 | −9.3 pp | MYGN |
| FY2010 | −12.2 pp | MYGN |
| FY2009 | −30.1 pp | MYGN |
| FY2008 | −14.6 pp | MYGN |
The higher net margin has changed hands between IDXX and MYGN over this period.
18 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MYGN's net margin has been more volatile than IDXX's over the 18 comparable fiscal years — 25.4 percentage points of standard deviation against 4.6.
18 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between IDXX and MYGN over these 18 fiscal years — IDXX led in 10 and MYGN in 8.
18 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
IDXX's return on equity has been more volatile than MYGN's over the 13 comparable fiscal years — 37.5 percentage points of standard deviation against 27.6.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between IDXX and MYGN over these 13 fiscal years — IDXX led in 12 and MYGN in 1.
13 of 18 comparable fiscal years — a year missing data on either side is not counted.